Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
302.11
-6.40 (-2.07%)
At close: Apr 28, 2026, 4:00 PM EDT
306.99
+4.88 (1.62%)
After-hours: Apr 28, 2026, 7:41 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 27 analysts with 12-month price forecasts for Alnylam Pharmaceuticals stock have an average target of 471, with a low estimate of 330 and a high estimate of 583. The average target predicts an increase of 55.90% from the current stock price of 302.11.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock from 28 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 13 | 13 | 13 | 12 |
| Buy | 10 | 10 | 10 | 10 | 10 | 10 |
| Hold | 4 | 5 | 5 | 5 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 29 | 28 | 28 | 29 | 28 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $515 → $505 | Strong Buy | Maintains | $515 → $505 | +67.16% | Apr 13, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $425 | Strong Buy | Maintains | $425 | +40.68% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $510 | Strong Buy | Reiterates | $510 | +68.81% | Mar 25, 2026 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $522 → $330 | Strong Buy → Hold | Downgrades | $522 → $330 | +9.23% | Mar 16, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $510 | Strong Buy | Reiterates | $510 | +68.81% | Feb 18, 2026 |
Financial Forecast
Revenue This Year
5.67B
from 3.71B
Increased by 52.67%
Revenue Next Year
7.46B
from 5.67B
Increased by 31.48%
EPS This Year
6.83
from 2.33
Increased by 192.95%
EPS Next Year
10.75
from 6.83
Increased by 57.53%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 6.5B | 9.5B | ||||||
| Avg | 5.7B | 7.5B | ||||||
| Low | 5.1B | 6.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 74.0% | 67.1% | ||||||
| Avg | 52.7% | 31.5% | ||||||
| Low | 37.4% | 14.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 9.86 | 15.74 | ||||||
| Avg | 6.83 | 10.75 | ||||||
| Low | 3.57 | 6.72 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 323.2% | 130.6% | ||||||
| Avg | 193.0% | 57.5% | ||||||
| Low | 53.1% | -1.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.